Stockreport

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Windtree Therapeutics, Inc.  (WINT) 
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: windtreetx.investorroom.com
PDF Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step [Read more]